Is EYED PHARMA still active?

Yes, EYED PHARMA is currently active.

What does EYED PHARMA do?

EYED PHARMA's registered main activities are Research and experimental development on biotechnology, Retail sale of other new goods n.e.c., and Retail sale of medical and orthopaedic goods, except corrective glasses, lenses and sunglasses. It is also registered for 1 additional activity.

Where is EYED PHARMA registered?

EYED PHARMA's registered address is Boulevard de Patience et Beaujonc 3 box 9, 4000 Liège, Belgium.

How many employees does EYED PHARMA have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2025), EYED PHARMA reported 29 full-time equivalent employees.

What is EYED PHARMA's annual turnover?

EYED PHARMA's most recently filed annual turnover (fiscal year ending 31 Dec 2025) was €10,494,903.

Did EYED PHARMA make a profit or a loss?

EYED PHARMA's most recently filed annual accounts (fiscal year ending 31 Dec 2025) reported a loss of €6,921,488.

When did EYED PHARMA last file annual accounts?

EYED PHARMA's most recently filed annual accounts cover the fiscal year ending 31 Dec 2025.

Is EYED PHARMA B Corp certified?

We have no B Corp certification on file for EYED PHARMA.

Does EYED PHARMA hold Fairtrade certification?

No, EYED PHARMA does not currently hold Fairtrade certification.

EYED PHARMA

Q: When was EYED PHARMA founded?

EYED PHARMA was founded on 20 Dec 2012, making it 13 years old.

BE 0508.599.605

Copied!

NV/SA

Status

Active

Founded

20 Dec 2012

Size

Medium · 29 FTE

Age

13 yrs

Main activity

Research and experimental development on biotechnology

Activities

4 activities

Research and experimental development on biotechnologyRetail sale of other new goods n.e.c.Retail sale of medical and orthopaedic goods, except corrective glasses, lenses and sunglassesResearch and experimental development on other natural sciences and engineering

Financials

Turnover2025

€10.5M-10.8%

Profit / Loss2025

−€6.9M+0.3%

Equity2025

€17.4M-23.8%

2025	2024	2023	2022
€10,494,903-10.8%	€11,761,713	—	—
-€6,921,488+0.3%	-€6,940,910-15%	-€6,034,167+4.4%	-€6,310,755
€17,370,564-23.8%	€22,782,731-17.2%	€27,522,992+68.9%	€16,296,064
€33,242,885+70%	€19,549,961+89%	€10,343,014-4.3%	€10,813,293
€1,300,599+7.1%	€1,214,166+17.5%	€1,033,545-70.2%	€3,473,979
29-13.4%	33.5-1.5%	34-15%	40
€361,893+3.1%	€351,096	—	—

Frequently asked questions

01What is EYED PHARMA's official registered name?

EYED PHARMA.

02What is EYED PHARMA's enterprise number (VAT number)?

BE 0508.599.605.

03What is EYED PHARMA's legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

04When was EYED PHARMA founded?

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

Financial statements

	2025	2024	2023	2022
Income statement
	€10,494,903-10.8%	€11,761,713	—	—
	29-13.4%	33.5-1.5%	34-15%	40
	€361,893+3.1%	€351,096	—	—
	€531,035+109%	€254,123-76.9%	€1,100,047+0.7%	€1,092,560
	€3,152,716-22.3%	€4,060,087-10.6%	€4,540,082+10.3%	€4,117,173
	€151,814-41.3%	€258,619+309.6%	€63,138-69.8%	€209,345
	-€8,165,982+1.7%	-€8,308,907-7.1%	-€7,755,716-5.3%	-€7,362,960
	—	—	—	-€4,558,818
	-€6,921,488+0.3%	-€6,940,910-15%	-€6,034,167+4.4%	-€6,310,755
Profitability
	5.1%+134.2%	2.2%	—	—
	-66.0%-11.8%	-59.0%	—	—
	-39.8%-30.8%	-30.5%-39%	-21.9%+43.4%	-38.7%
	-13.7%+16.6%	-16.4%-2.9%	-15.9%+31.5%	-23.3%
Solvency
	€50,613,449+19.6%	€42,332,692+11.8%	€37,866,006+39.7%	€27,109,357
	€342,244+10.6%	€309,5820%	€309,574-35.3%	€478,580
	€11,650-19.9%	€14,550-57.3%	€34,110-53.8%	€73,765
	€17,370,564-23.8%	€22,782,731-17.2%	€27,522,992+68.9%	€16,296,064
	34.3%-36.2%	53.8%-26%	72.7%+20.9%	60.1%
	€24,917,683+140.8%	€10,346,986+127.2%	€4,554,250+104.3%	€2,228,881
	1.43+215.9%	0.45+174.5%	0.17+21%	0.14
	€33,242,885+70%	€19,549,961+89%	€10,343,014-4.3%	€10,813,293
	1.91+123%	0.86+128.3%	0.38-43.4%	0.66
Liquidity
	€1,300,599+7.1%	€1,214,166+17.5%	€1,033,545-70.2%	€3,473,979
	—	—	€596,833+31.2%	€454,955
	€314,569+5.1%	€299,185-78.1%	€1,365,285-11.6%	€1,544,765
	€1,310,174-45.8%	€2,418,586-35.8%	€3,768,342+82.7%	€2,063,144
	€8,154,408-11.3%	€9,194,304+59.2%	€5,776,437-32.4%	€8,544,034
	1.83+57.7%	1.16-44%	2.07+276.9%	0.55
	€8,169,364+207.1%	€2,659,989-63.1%	€7,209,615>1000%	-€402,657
Efficiency
	11 days+17.9%	9 days	—	—
Profit appropriation
	-€19,896,564-53.3%	-€12,975,077-115%	-€6,034,167+68.3%	-€19,033,744

Sources

NBB — Nationale Bank van België

	2025	2024	2023	2022
Income statement
	€10,494,903-10.8%	€11,761,713	—	—
	29-13.4%	33.5-1.5%	34-15%	40
	€361,893+3.1%	€351,096	—	—
	€531,035+109%	€254,123-76.9%	€1,100,047+0.7%	€1,092,560
	€3,152,716-22.3%	€4,060,087-10.6%	€4,540,082+10.3%	€4,117,173
	€151,814-41.3%	€258,619+309.6%	€63,138-69.8%	€209,345
	-€8,165,982+1.7%	-€8,308,907-7.1%	-€7,755,716-5.3%	-€7,362,960
	—	—	—	-€4,558,818
	-€6,921,488+0.3%	-€6,940,910-15%	-€6,034,167+4.4%	-€6,310,755
Profitability
	5.1%+134.2%	2.2%	—	—
	-66.0%-11.8%	-59.0%	—	—
	-39.8%-30.8%	-30.5%-39%	-21.9%+43.4%	-38.7%
	-13.7%+16.6%	-16.4%-2.9%	-15.9%+31.5%	-23.3%
Solvency
	€50,613,449+19.6%	€42,332,692+11.8%	€37,866,006+39.7%	€27,109,357
	€342,244+10.6%	€309,5820%	€309,574-35.3%	€478,580
	€11,650-19.9%	€14,550-57.3%	€34,110-53.8%	€73,765
	€17,370,564-23.8%	€22,782,731-17.2%	€27,522,992+68.9%	€16,296,064
	34.3%-36.2%	53.8%-26%	72.7%+20.9%	60.1%
	€24,917,683+140.8%	€10,346,986+127.2%	€4,554,250+104.3%	€2,228,881
	1.43+215.9%	0.45+174.5%	0.17+21%	0.14
	€33,242,885+70%	€19,549,961+89%	€10,343,014-4.3%	€10,813,293
	1.91+123%	0.86+128.3%	0.38-43.4%	0.66
Liquidity
	€1,300,599+7.1%	€1,214,166+17.5%	€1,033,545-70.2%	€3,473,979
	—	—	€596,833+31.2%	€454,955
	€314,569+5.1%	€299,185-78.1%	€1,365,285-11.6%	€1,544,765
	€1,310,174-45.8%	€2,418,586-35.8%	€3,768,342+82.7%	€2,063,144
	€8,154,408-11.3%	€9,194,304+59.2%	€5,776,437-32.4%	€8,544,034
	1.83+57.7%	1.16-44%	2.07+276.9%	0.55
	€8,169,364+207.1%	€2,659,989-63.1%	€7,209,615>1000%	-€402,657
Efficiency
	11 days+17.9%	9 days	—	—
Profit appropriation
	-€19,896,564-53.3%	-€12,975,077-115%	-€6,034,167+68.3%	-€19,033,744

2025

2024

2023

2022

Income statement

€10,494,903-10.8%

€11,761,713

—

29-13.4%

33.5-1.5%

34-15%

€361,893+3.1%

€351,096

—

€531,035+109%

€254,123-76.9%

€1,100,047+0.7%

€1,092,560

€3,152,716-22.3%

€4,060,087-10.6%

€4,540,082+10.3%

€4,117,173

€151,814-41.3%

€258,619+309.6%

€63,138-69.8%

€209,345

-€8,165,982+1.7%

-€8,308,907-7.1%

-€7,755,716-5.3%

-€7,362,960

—

-€4,558,818

-€6,921,488+0.3%

-€6,940,910-15%

-€6,034,167+4.4%

-€6,310,755

Profitability

5.1%+134.2%

2.2%

—

-66.0%-11.8%

-59.0%

—

-39.8%-30.8%

-30.5%-39%

-21.9%+43.4%

-38.7%

-13.7%+16.6%

-16.4%-2.9%

-15.9%+31.5%

-23.3%

Solvency

€50,613,449+19.6%

€42,332,692+11.8%

€37,866,006+39.7%

€27,109,357

€342,244+10.6%

€309,5820%

€309,574-35.3%

€478,580

€11,650-19.9%

€14,550-57.3%

€34,110-53.8%

€73,765

€17,370,564-23.8%

€22,782,731-17.2%

€27,522,992+68.9%

€16,296,064

34.3%-36.2%

53.8%-26%

72.7%+20.9%

60.1%

€24,917,683+140.8%

€10,346,986+127.2%

€4,554,250+104.3%

€2,228,881

1.43+215.9%

0.45+174.5%

0.17+21%

0.14

€33,242,885+70%

€19,549,961+89%

€10,343,014-4.3%

€10,813,293

1.91+123%

0.86+128.3%

0.38-43.4%

0.66

Liquidity

€1,300,599+7.1%

€1,214,166+17.5%

€1,033,545-70.2%

€3,473,979

—

€596,833+31.2%

€454,955

€314,569+5.1%

€299,185-78.1%

€1,365,285-11.6%

€1,544,765

€1,310,174-45.8%

€2,418,586-35.8%

€3,768,342+82.7%

€2,063,144

€8,154,408-11.3%

€9,194,304+59.2%

€5,776,437-32.4%

€8,544,034

1.83+57.7%

1.16-44%

2.07+276.9%

0.55

€8,169,364+207.1%

€2,659,989-63.1%

€7,209,615>1000%

-€402,657

Efficiency

11 days+17.9%

9 days

—

Profit appropriation

-€19,896,564-53.3%

-€12,975,077-115%

-€6,034,167+68.3%

-€19,033,744

EYED PHARMA

Activities

Financials

Frequently asked questions

All locations

Financial statements

All locations

Financial statements